Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03760276
Other study ID # Voriconazole_CYP2C19
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 20, 2018
Est. completion date October 28, 2018

Study information

Verified date November 2018
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A pilot study was performed to evaluate the appropriateness of the voriconazole dosing regimen based on the population pharmacokinetic model and the influence of sex on the pharmacokinetics of voriconazole


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date October 28, 2018
Est. primary completion date October 28, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria:

- Those who have been informed of the nature of the trial and have voluntarily agreed to participate in this study and have signed an IRB approved consent before all screening tests

- Healthy Korean male and female volunteers aged 20 to 45

- Those with a body weight of 50 kg or more and less than 90 kg and a body mass index (BMI) of 18 or more and less than 27 (BMI(kg/m2) = body weight (kg)/{height(m)}2

- CYP2C19 EM or PM

Exclusion Criteria:

- Subjects with clinical evidence of significant respiratory, circulatory, renal, hepatic, endocrine, blood, neuropsychiatric, skeletal or other chronic diseases, alcohol or drug addiction

- Subjects with a history of gastrointestinal disorders (Crohn's disease, ulcers, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal surgery or hernia surgery) that may affect the absorption of the test drug

- Those with a history of substance abuse within the last 2 months

- Those who have taken any prescribed medicines or herbal medicines within 2 weeks prior to the date of the first medicines, or those taking any general medicines (OTC) or vitamin preparations (eligible if the other conditions are reasonable according to the judgment of the investigator)

- Those who donate blood within 30 days before the date of the first dose or who have participated in the clinical study of other clinical trial drugs or marketed drugs within 3 months

- Those who have had significant adverse reactions such as hypersensitivity reactions to azole drugs including drugs for clinical research

- Those who are not planning on or planning to have a pregnancy during the trial and are not able to use a recognized method of contraception (eg, sterilization surgery of the person and partner, intrauterine contraceptive device, or diaphragm contraception (such as diaphragm or condom use)

- Persons who are continuously drinking (21 units / week, 1 unit = 10 g of pure alcohol) or who can not abstain from 3 days before the first dose to the end of the clinical trial

- Those who smoked more than 10 cigarettes per day for the last 3 months or who can not quit smoking 3 days before the first dose

- Those who consume grapefruit / caffeine-containing food within 3 days of the first dose or who cannot be prohibited during the clinical study period

- Screening tests for urine pregnancy (ß-hCG) positive or lactating women

- Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

- A person who is found to be unsuitable for participation in clinical research due to safety laboratory results or other reasons

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Voriconazole Oral Product (Vfend®)
To be determined mg of Voriconazole (Vfend®, anti-fungal agent)

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Clinical Trial Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak plasma concentration (Cmax) Pharmacokinetic sampling after administration of drugs from day 1 to day 7 Day 1 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours, Day 5 12 hours, Day 6 0, 12 hours, Day 7 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Primary Area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast) Pharmacokinetic sampling after administration of drugs from day 1 to day 7 Day 1 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours, Day 5 12 hours, Day 6 0, 12 hours, Day 7 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Secondary Genetic polymorphisms of CYP2C9 and CYP3A4 Exploratory evaluation Day 1 0 hour
Secondary Hepatic safety marker of miRNA-122 Exploratory safety evaluation Day 1 0 hour, Day 5 12 hour, Day 7 12 hour
Secondary Safety and tolerability evaluation by monitoring adverse events (number of subjects and cases) Safety and tolerability evaluation Day 1 to Day 12
Secondary Physical examination (list of current medications) Safety and tolerability evaluation Day 1 to Day 12
Secondary Physical examination (list of any symptoms or pain) Safety and tolerability evaluation Day 1 to Day 12
Secondary Physical examination (Medical and surgical history) Safety and tolerability evaluation Day 1 to Day 12
Secondary Evaluation of Vital signs (body temperature °C) Safety and tolerability evaluation Day 1 to Day 12
Secondary Evaluation of Vital signs (blood pressure mmHg) Safety and tolerability evaluation Day 1 to Day 12
Secondary Evaluation of Vital signs (pulse (heart rate, beats per minute)) Safety and tolerability evaluation Day 1 to Day 12
Secondary Evaluation of Vital signs (breathing rate (respiratory rate, beats per minute)) Safety and tolerability evaluation Day 1 to Day 12
Secondary Safety and tolerability evaluation by 12-lead ECG (P wave, PR interval, QRS complex, J-point, ST segment, T wave, Corrected QT interval, U wave) Safety and tolerability evaluation Day 1 to Day 12
Secondary number of participants with abnormal laboratory values (hematologic, chemical, urine) Safety and tolerability evaluation Day 1 to Day 12
See also
  Status Clinical Trial Phase
Completed NCT03641131 - Ampholipad Real-World Data in Taiwan
Not yet recruiting NCT03292224 - Systemic Fungal Infections in ICU Patients N/A
Completed NCT01371656 - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Phase 3
Completed NCT00936117 - Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Phase 2
Completed NCT00740389 - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. Phase 1
Completed NCT03857399 - Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin Phase 2
Not yet recruiting NCT04215458 - Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases N/A
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT02957929 - Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally Phase 1
Completed NCT01419678 - Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients N/A
Recruiting NCT00333645 - Prophylaxis With Caspofungin in High-Risk Liver Transplantation Phase 2
Not yet recruiting NCT03650439 - Fungal Infections in Patients With Hematological Malignancies
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT00811642 - Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) Phase 3
Withdrawn NCT00430469 - Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients Phase 1/Phase 2
Terminated NCT00386997 - ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Phase 4
Completed NCT00514358 - Fluconazole Pharmacokinetics in Infants Phase 1
Completed NCT04166669 - A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 Phase 1
Recruiting NCT05150327 - Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
Completed NCT02387983 - Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) Phase 1

External Links